Fig. 3. Survival charts in regard of chemotherapy and K-ras mutation. Overall survival (A, B) and liver progression-free survival (C, D) charts according to wild or mutated K-ras oncogene and whether neoadjuvant chemotherapy is administired or not prior to thermal ablation. Emphatic effect of mutated K-ras oncogene is clearly observed (A, C), while no significant effect of neoadjuvant chemotherapy for liver metastasis on survival is observed (B, D).
© Int J Gastrointest Interv
pISSN 2636-0004
